The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback